CONTRASTING FRAMINGHAM RISK EQUATIONS IN TYPE 2 DIABETES USING THE IQVIA CORE DIABETES MODEL
Author(s)
Monteiro S1, Ramos M2, Altrabsheh E3, Gurjar K4, Olivieri AV5, Lamotte M6
1IQVIA, London, LON, UK, 2IQVIA, Zaventem, VOV, Belgium, 3IQVIA, London, UK, 4IQVIA, Gurgaon, India, 5IQVIA, Basel, Switzerland, 6IQVIA, Zaventem, Belgium
OBJECTIVES The IQVIA Core Diabetes Model (CDM) contains several risk equations to predict cardiovascular events, including a set of individual end-point Framingham (EPF) equations estimating the incidence of coronary heart disease (CHD), stroke and congestive heart failure (CHF). In 2008, the same Framingham Heart Study investigators published a generalized algorithm to calculate a composite cardiovascular disease (CVD) risk. The updated CDM 9.5 version includes this general Framingham (GF) CVD equation. The current study compared the outcomes obtained with GF against EPF equations. METHODS Baseline characteristics and treatment effects from the observational EDGE study comparing metformin + vildagliptin (M+V) with metformin + sulphonylurea (M+S) were employed: mean age 57.8 years, diabetes duration 6 years, 54.8% male, HbA1c 8.2% and BMI 29kg/m2; HbA1c reductions were -0.99% and -1.19%, with changes of -0.3kg and -1.6kg in body weight for M+S and M+V, respectively. Basal insulin rescue therapy was applied to both arms when HbA1c surpassed 7.5%. A dynamic risk-factor-related weighting algorithm, based on UKPDS68, matched the composite CVD risk score from GF to the individual end-points of CDM. UK 2018 costs were applied; costs and health benefits were discounted at 3.5% per year. RESULTS Using GF, mean life expectancy (-0.4 years) and QALY (-0.3) decreased in both arms due to higher cumulative incidence of CVD (+10%) and consequent increase in CVD-related mortality (+6%). Repartition of events also changed, as incidence of CHF was reduced (-18%), while stroke (+17%) and MI (+12%) increased. Costs increased by 6%. However, impact on incremental cost-utility ratio (ICUR) was minor, decreasing from 10,288GBP/QALY in EPF to 10,133GBP/QALY in GF. CONCLUSIONS The use of GF along with a risk-factor weighting algorithm resulted in higher incidence of CVD, with a different distribution of events compared to applying the EPF equations. Despite important differences in total costs and disease incidence, the ICUR was maintained.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PDB35
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders, Diabetes/Endocrine/Metabolic Disorders